Clinical Neuropharmacology 2009-01-01

Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine.

Toshiki Mizuno, Masaki Kondo, Noriko Ishigami, Aiko Tamura, Masahiro Itsukage, Hideyuki Koizumi, Reina Isayama, Akiko Hosomi, Yoshinari Nagakane, Takahiko Tokuda, Eizo Sugimoto, Yo Ushijima, Masanori Nakagawa

Index: Clin. Neuropharmacol. 32(2) , 113-6, (2009)

Full Text: HTML

Abstract

A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients.